Insulet Corporation NMS · PODD
Price alert —
Sign in to get a one-time email the moment PODD crosses your price. Free accounts included.
Sign in / create a free accountInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
PODD last traded at $164.06, down 0.2% on the day; that's in the lower part of its 52-week range ($138.79–$288.98). Right now it's trading close to its recent average, with no strong stretch in either direction.
The next scheduled earnings report (2026-08-05) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 upper, +0.87 ATR from EMA21 — no notable pattern
- · Stochastic bull cross
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC1 upper stretch — light pop
- · RSI hook from overbought (58)
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 58), the trend is quiet (ADX 15), and volume is about normal (0.9×). On the business side, revenue is growing 34% year over year and the business keeps about 9 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $194.33 (fair range $73–$194); today's price leaves a +17% cushion below that estimate. The model's verdict is “Undervalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Current ratio 2.81 (antifragile)
- ✓ Goodwill 2% of assets (organic growth)
- ✓ Positive retained earnings
- ✓ Gross margin 71% (pricing power)
- ⚠ Debt exceeds cash
- ⚠ Receivables growing faster than revenue
Price implies ~22% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
PODD is a $11.4 billion company, priced at 38× last year's earnings.
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-06
- EPS (act / est)
- 1.42 / 1.19
- Surprise
- +19.3%
- Next report
- 2021-05-06
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucos…